Ref: GLL/BSE/2026-27/Aug -

Date: August 14, 2026

To
The General Manager,
Corporate Relations Department,
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, **Mumbai – 400001**.
Maharashtra State, India.
Script Code: 531739

To
The Listing Manager,
The Ahmedabad Stock Exchange Limited
A-2, Kamdhenu Complex, Opp. Sahajanand
College, 120 Feet Ring Road, Panjara Pol,
Ambawadi, **Ahmedabad - 380015**.
Gujarat State, India.
Script Code:

To
The Calcutta Stock Exchange Limited,
#7, Lyons Range, Murgighata,
Dalhousie, **Kolkata - 700001**,
West Bengal State, India.
Scrip Code: 26178

Dear Sir/Madam,

Sub: Outcome of the Board Meeting of Gennex Laboratories Limited – Scrip Code: 531739/GENNEX

Ref: Regulation 29, 33 & 47 of the SEBI (LODR) 'Regulations, 2015.

In just concluded Meeting of Board of Directors, the Board Approved and considered the following items:

1. Unaudited (Standalone and Consolidated) Financial Statements for the Quarter ended June 30, 2026 (annexed herewith);
2. Limited review reports from the Statutory Auditor on Unaudited (Standalone and Consolidated) Financial Statements for the Quarter ended June 30, 2026 (annexed here with);
3. Other Business items.

We hereby submit that the Board Meeting had commenced at 4:00 PM and concluded at 4.40 PM.

This intimation is also uploaded on the Company website: www.gennexlab.com.

We request you to take the above information on record and acknowledge the receipt of the same.

Thanking you,
Yours faithfully
For Gennex Laboratories Limited

Dinesh Kumar Kejriwal
Company Secretary & Compliance Officer
Membership #A19293

GENNEX LABORATORIES LIMITED

Registered Office : Sy.No.133, Bollaram, Jinnaram Mandal,
Dist : Sangareddy, Telangana - 502 325. INDIA
Tel. No.+91-40-67334400-30, Fax: +91-40-67334433, Email: info@gennexlab.com website: www.gennexlab
CIN : L24230TG1990PLC011168

Statement of Standalone and Consolidated Unaudited Financial Results for the Quarter Ended 30th June, 2026

(Rs. In Lacs)

S No.	PARTICULARS	Standalone				Consolidated			
		Quarter ended			Year ended	Quarter ended			Year ended
		30.06.2026	31.03.2026	30.06.2025	31.03.2026	30.06.2026	31.03.2026	30.06.2025	31.03.2026
		(Unaudited)	(Audited)	(Unaudited)	(Audited)	(Unaudited)	(Audited)	(Unaudited)	(Audited)
1	**Income**								
	Revenue from Operations	3,467.79	3,671.41	2,564.00	11,985.67	3,984.17	6,095.50	3,417.75	17,274.09
	Other Income	199.70	129.79	226.44	814.01	200.82	131.87	227.74	824.58
	Total Income	**3,667.49**	**3,801.20**	**2,790.44**	**12,799.68**	**4,184.99**	**6,227.37**	**3,645.49**	**18,098.67**
2	**Expenses**								
(a)	Cost of material consumed	2,601.43	3,383.62	1,826.97	9,682.79	2,967.25	5,528.78	2,381.96	13,961.93
(b)	Purchase of stock-in-trade	-	-	-	-	-	-	-	-
(c)	Changes in stock-in-trade and Work in Progress and stock in trade	93.83	-252.90	-98.80	-929.37	-3.54	-266.66	-162.26	-1,109.46
(d)	Employees Cost	166.47	82.82	188.03	667.44	197.57	117.10	269.02	803.89
(e)	Depreciation	23.92	34.94	19.87	246.69	56.89	107.66	50.40	419.82
(f)	Finance Cost	50.88	63.11	59.15	96.76	89.97	116.05	97.90	264.80
(g)	Other Expenses	310.43	139.28	310.26	1,151.67	385.21	127.69	421.82	1,373.92
	Total Expenses	**3,246.96**	**3,450.87**	**2,305.49**	**10,915.98**	**3,693.35**	**5,730.62**	**3,058.84**	**15,714.90**
3	**Total Profit before exceptional Items & Tax.**	**420.53**	**350.33**	**484.95**	**1,883.70**	**491.64**	**496.75**	**586.64**	**2,383.77**
4	Exceptional items	-	-	-	-	-	-	-	-
	Corporate Social Responsibilites	-	**30.00**	-	60.00	-	**30.00**	-	**60.00**
5	**Total profit before tax**	**420.53**	**320.33**	**484.95**	**1,823.70**	**491.64**	**466.75**	**586.64**	**2,323.77**
6	Tax expense for earlier years	-	-	-	-	-	-	-	-
7	Curent tax	25.00	-	70.00	190.00	25.00	-	85.00	205.00
8	Deferred Tax	-	20.89	-	20.89	-	20.89	-	20.89
9	**Total Tax Expenses**	**25.00**	**20.89**	**70.00**	**210.89**	**25.00**	**20.89**	**85.00**	**225.89**
10	**Net profit (Loss)**	**395.53**	**299.44**	**414.95**	**1,612.81**	**466.64**	**445.86**	**501.64**	**2,097.88**
11	Share of profit (loss) of associates and joint ventures accounted for using equity method	-	-	-	-	-	-	-	-
12	**Total Profit (losss) for period**	**395.53**	**299.44**	**414.95**	**1,612.81**	**466.64**	**445.86**	**501.64**	**2,097.88**
13	Other comprehensive income net of taxes	-	-	-	-	-	-	-	-
14	Total Comprehensive income for the period	-	5.19	-	5.19	-	5.19	-	5.19
15	**Total Comprehensive income for the period attributable to**	**395.53**	**304.63**	**414.95**	**1,618.00**	**466.64**	**451.05**	**501.64**	**2,103.07**
	Comprehensive income for the period attributable to owners of parent	-	-	-	-	**431.79**	**379.02**	**459.16**	**1,850.69**

	Total comprehensive income for the period attrributable to owners of parent non controlling interests	-	-	-	-	34.85	72.03	42.48	252.38
16	**Details of equity share capital**								
	Paid up equity share capital	2,429.48	2,429.48	2,314.48	2,429.48	2,429.48	2,429.48	2,314.48	2,429.48
	Face value of equity share capital in Rs	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00
17	**Earnings per share**								
	- Basic	0.163	0.125	0.179	0.666	0.192	0.156	0.217	0.762
	- Diluted	0.163	0.125	0.171	0.666	0.192	0.156	0.206	0.762

Notes to the results:

1. The above unaudited financial results have been reviewed by the Audit Committee of its meeting held on 14.08.2026 and the same were approved and taken on record by the Board of Directors at its meeting held on the same day.

2. The Statutory Auditors of the Company have carried out the Limited review of the above unaudited financial results for the Quarter ended June 30, 2026.

3. The above results have been prepared in accordance with the Companies (Indian Accounting Standards) Rules,2015 (IND-AS) prescribed u/s 133 of the Companies Act, 2013 and other recognished accounting practices and policies to the extent applicable.

4. The management has assessed the Identification of reportable segments in accordance with the requirement of the Ind AS 108 Primary segment and believes that the Company has only one reportable segment namely "Bulk Drugs,Bioteck Products and Intermediates". Previous period's figures have been rearranged/regrouped wherever necessary.

5. Adjustment of actuarial valuation in respect of compliance with Accounting Standard- IAS-19-'Employee Benefits' is to be done at the year end.

6. Quarter ended 30th June,2026 Consolidated figures includes Sales (Net) of 271.93 lacs & Purchase(Net) of Rs 41.20 lacs to subsidiary "Deccan Remedies Ltd".

7. The quarterly unaudited financial results for the Quarter ended June 30, 2026 are available on the Company's Website i.e; www.gennexlab.com and also available on BSE website i.e; www.bseindia.com.

For and on behalf of the Board
For Gennex Laboratories Limited

ARIHANT BAID

Digitally signed by ARIHANT BAID
Date: 2026.08.14 16:49:29 +05'30'

Arihant Baid
Managing Director

Place: Hyderabad
Date: 14.08.2026

R Pugalia & Company
Chartered Accountants
20 E Lake Road Kolkata-700029

Limited Review report on Unaudited Consolidated financial results for quarter ended 30th June, 2026 of the Company pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation 2015.

To
The Board of Directors,
M/s. Gennex Laboratories Limited,
Hyderabad.

1. We have reviewed the accompanying Statement of Unaudited Consolidated Financial Results of **M/s. Gennex Laboratories Limited** ("the Company") and its share of the net profit/(loss) after tax and total comprehensive income / loss of its Subsidiary for the quarter ended June 30, 2026, and for the period from April 01, 2026 to June 30, 2026 ("the Statement") being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended. Attention is drawn to the fact that the consolidated figures for the corresponding quarter ended June 30, 2026 as reported in these financial results have been approved by the Company's Board of Directors, but have not been subjected to review.

2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Act, and consequently does not enable us to obtain assurance that we would become aware of all significant

matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

4. The Statement includes the results of Deccan Remedies Limited. (Subsidiary Company)

5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration referred to in paragraph 6 below, nothing has come to our attention that causes us to believe that the accompanying Statement. prepared in accordance with recognition and measurement principles laid down in the aforesaid Indian Accounting Standard specified under Section 133 of the Companies Act, 2013, as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

6. The accompanying unaudited consolidated financial results include the interim financial results and other financial information in respect of 1 subsidiary, whose interim financial results (excluding consolidation eliminations) reflect total revenues of ₹ 517.50 Lakhs and total net profit after tax of ₹ 71.11 Lakhs for the quarter ended June 30, 2026, as considered in the unaudited consolidated financial results. These interim financial results have been reviewed by other auditors whose reports have been furnished to us by the Management, and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of this subsidiary, is based solely on the reports of the other auditors. According to the information and explanations given to us by the Management, these interim financial results are not material to the Group. Our conclusion on the Statement is not modified in respect of the above matter.

For R PUGALIA & COMPANY
Chartered Accountants
Firm Registration No.318188E

R. PUGALIA & CO. CHARTERED ACCOUNTANTS KOLKATA 053972

RAJEEV KUMAR PUGALIA
Memberhip No.053972
Place: Kolkata
Date: 14th August 2026
UDIN: 26053972BCAWNE7253

R Pugalia & Company
Chartered Accountants
20 E Lake Road Kolkata-700029

Limited Review report on Unaudited Standalone financial results for quarter ended 30th June, 2026 of the Company pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation 2015.

To
The Board of Directors,
M/s. Gennex Laboratories Limited,
Hyderabad.

1. We have reviewed the accompanying Statement of Unaudited Standalone financial results of **Gennex Laboratories Limited** ("the Company") for the Quarter ended June 30, 2026 and for the period from April 01, 2026 to June 30, 2026 ("the statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended ("the Listing Regulations") read with SEBI Circular No. CIR/CFD'CMDI/44/2019 dated March 29, 2019 ("the Circular").

2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Act, and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

4. Based on our review conducted as stated in paragraph 3 above, nothing has come to our attention, except as stated below, that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and

measurement principles laid down in the aforesaid Indian Accounting Standard ("Ind AS") specified under Section 133 of the Companies Act, 2013, as amended, read with the Companies (Indian Accounting Standards) Rules, 2015 and other accounting principles and policies generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, read with SEBI Circular No. CIR/CFD/FAC/62/2016 dated July 05, 2016, including the manner in which it is to be disclosed, or that it contains any material misstatement.

5. Attention is drawn to the fact that the figures for the three months ended 31 March 2026 as reported in the Statement are the balancing figures between audited figures in respect of the full previous financial year and the published year to date figures up to the third quarter of the previous financial year. The figures up to the end of the third quarter of previous financial year had only been reviewed and not subjected to audit.

For R PUGALIA & COMPANY
Chartered Accountants
Firm Registration No.318188E

R. K. PUGALIA & CO. KOLKATA 053972 CHARTERED ACCOUNTANTS

RAJEEV KUMAR PUGALIA
Memberhip No.053972
Place: Kolkata
Date: 14th August 2026
UDIN: 26053972WGJOOV8398

Gennex Laboratories Limited

Segment Reporting (Country Wise)

The following table shows the distribution of the Company's revenue based on the location of the customers

(Rs. In Lakhs)

Particulars	Quarterly			Yearly
	30-Jun-26	31-Mar-26	30-Jun-25	31-Mar-26
ALGERIA			3.02	3.02
BANGLADESH			3.18	3.18
BARZIL				
BOLIVIA	4.18	1.75		1.75
COLOMBIA	350.6	204.05	339.86	917.04
CZECH REPUBLIC				
CHINA				
Ecuador	28.83			1.29
EGYPT	253.58	171.86	184.92	368.43
ELSALVADOR			64.65	82.29
GERMANY		13.98		13.98
GUATEMALA CITY	67.99	24.98	26.72	92.51
IRAN				
Jordan		8.91		11.7
MEXICO	37.65	200.64	127.21	337.82
PARGUE			2.29	2.64
PERU	89.75	15.35	96.01	184.85
RUSSIA	10	20	5	30
SAUDI ARABIA			36.3	36.3
SPAIN	2.67	5.13		7.66
SWITZERLAND				
TURKEY		0.65	1.04	1.69
THAILAND		103.35	24.99	140.5
UAE				
VIETNAM	81.72	285.36	287.29	1346.7
ZIMBABWE	3.74			
INDIA	**2537.08**	**2615.4**	**1361.52**	**8402.32**
	3,467.79	**3,671.41**	**2,564.00**	**11,985.67**

For Gennex Laboratories Limited

ARIHANT BAID

Digitally signed by ARIHANT BAID
Date: 2026.08.14 15:32:36 +05'30'

Arihant Baid
Managing Directors
DIN # 01171845

Date: 14-08-2026
Place: Hyderabad